Cipla

NSE: CIPLA · Pharma

₹1,489.50

▼ -0.70%

HOLD

Illustrative research · not investment advice Demo price · quote unavailable · Fundamentals and research: sample dataset (30 Oct 2026)

Price chart

Illustrative price history · not actual market candles

A. Company overview

Respiratory-focused global pharma company.

Market cap

₹2,26,79,910 Cr

Industry / Sector

Pharma

Segments

Website

Visit ↗

IndiaNorth AmericaAfrica

B. Fundamental analysis (illustrative)

Revenue growth

+4.26%

Net profit growth

+9.56%

Operating margin

19.52%

EBITDA margin

24.02%

ROE

10.69%

ROCE

15.42%

Debt / Equity

1.42

EPS

₹40.60

Operating cash flow

₹79,406 Cr

Working capital

₹41,941 Cr

5-year revenue & profit (₹ Cr)

C. Financial statements (illustrative)

₹ Cr	FY22	FY23	FY24	FY25	FY26
Revenue	3,51,862	3,72,721	4,36,249	4,59,071	5,24,265
EBITDA	71,806	73,635	91,785	1,08,973	1,25,923
Net profit	44,879	46,022	57,366	68,108	78,702
EPS (₹)	28.42	31.67	34.92	38.16	41.41

D. Valuation analysis

P/E

36.69

P/B

3.85

EV/EBITDA

11.96

Price/Sales

7.03

EPS

₹40.60

Dividend yield

1.71%

Peer comparison — Pharma

Company	CMP	P/E	P/B	ROE	D/E
Cipla	1,489.5	36.69	3.85	10.69%	1.42
Sun Pharmaceutical	1,781.5	55.43	3.1	22.33%	0.13
Dr. Reddy's Laboratories	1,276.25	54.23	4.39	18.22%	1.24
Divi's Laboratories	6,383.65	23.57	3.34	29.57%	0.89

E. Technical analysis

RSI (14)

32.69

MACD

2.28

Support

₹1,415.02

Resistance

₹1,578.87

Volume

1,60,18,980

Illustrative technical charts · not actual market history

Candlestick (last 50 sessions)

Price with 50-DMA & 200-DMA, volume

Fibonacci retracement levels

23.6% · ₹1558.85

38.2% · ₹1536.43

50.0% · ₹1518.31

61.8% · ₹1500.19

F. Shareholding pattern

Promoter66.76%

FII8.78%

DII5.36%

of which Mutual Funds3.52%

Public19.1%

G. SWOT analysis

Strengths

Established position in Pharma
ROE of 10.69% in demo data

Weaknesses

Elevated leverage
Cyclical exposure

Opportunities

Domestic demand growth
Expansion in India

Threats

Regulatory changes
Competitive intensity

Illustrative template points for demonstration.

H. Research conclusion

Financial strength

Moderate leverage to monitor

Business quality

Average capital efficiency

Valuation

Premium valuation

Growth

Sales growth of 4.26%

Risk assessment

High risk

Overall

Illustrative HOLD opinion · target ₹1,491.89 · stop loss ₹1,363.67

I. Corporate actions

Dividend history (₹/share)

Year	Dividend
FY22	20.38
FY23	21.91
FY24	23.43
FY25	24.96
FY26	26.49

Bonus, splits & announcements

Bonus history: none in demo dataset
Stock split history: none in demo dataset
Board meeting for quarterly results — demo announcement